Filip Aleksander Garbicz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 7 | 2020 | 3811 | 0.480 |
Why?
|
| Endothelial Cells | 2 | 2024 | 3592 | 0.460 |
Why?
|
| Pituitary Neoplasms | 2 | 2019 | 1326 | 0.400 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 5196 | 0.330 |
Why?
|
| Chromosome Segregation | 1 | 2023 | 230 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1437 | 0.200 |
Why?
|
| Sirtuin 1 | 1 | 2023 | 247 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2021 | 31 | 0.190 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2023 | 423 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8664 | 0.160 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2019 | 49 | 0.160 |
Why?
|
| ACTH-Secreting Pituitary Adenoma | 1 | 2019 | 64 | 0.160 |
Why?
|
| Gonadotropins | 1 | 2019 | 241 | 0.150 |
Why?
|
| Matrix Metalloproteinase 16 | 1 | 2017 | 4 | 0.150 |
Why?
|
| Oncogenes | 2 | 2021 | 1236 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2017 | 72 | 0.140 |
Why?
|
| Endometrial Neoplasms | 2 | 2017 | 1386 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2024 | 2414 | 0.140 |
Why?
|
| beta Catenin | 1 | 2022 | 1047 | 0.140 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2016 | 97 | 0.140 |
Why?
|
| Prostatic Hyperplasia | 1 | 2020 | 523 | 0.140 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2016 | 59 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 998 | 0.130 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2015 | 12 | 0.130 |
Why?
|
| Epigenomics | 1 | 2021 | 961 | 0.130 |
Why?
|
| Oncogene Fusion | 1 | 2015 | 84 | 0.120 |
Why?
|
| Cell Proliferation | 4 | 2024 | 10486 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2024 | 2634 | 0.110 |
Why?
|
| Endometriosis | 1 | 2021 | 874 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 3952 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2015 | 1426 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2021 | 3702 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2020 | 11230 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5707 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 7609 | 0.050 |
Why?
|
| Arginase | 1 | 2022 | 81 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 6982 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2021 | 199 | 0.040 |
Why?
|
| Neoplasms | 2 | 2021 | 22389 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2019 | 130 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9442 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2023 | 763 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 11932 | 0.040 |
Why?
|
| Endometrium | 1 | 2021 | 406 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 6401 | 0.040 |
Why?
|
| Humans | 13 | 2024 | 768970 | 0.040 |
Why?
|
| Cell Line, Tumor | 3 | 2019 | 17173 | 0.030 |
Why?
|
| Cyclins | 1 | 2019 | 606 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2021 | 2631 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 30266 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2019 | 23653 | 0.030 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 462 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2017 | 515 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 59739 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 874 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2019 | 1246 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 9213 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 6131 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1120 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3621 | 0.030 |
Why?
|
| Cholesterol | 1 | 2022 | 2913 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 11116 | 0.030 |
Why?
|
| Animals | 5 | 2022 | 169335 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 3629 | 0.020 |
Why?
|
| Homeostasis | 1 | 2022 | 3347 | 0.020 |
Why?
|
| Aged | 3 | 2020 | 171786 | 0.020 |
Why?
|
| Mice | 3 | 2022 | 82072 | 0.020 |
Why?
|
| Female | 6 | 2021 | 397515 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 60131 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2021 | 8317 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2018 | 1356 | 0.020 |
Why?
|
| Zebrafish | 1 | 2021 | 3037 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2942 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2022 | 3608 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2022 | 12174 | 0.020 |
Why?
|
| Adult | 3 | 2021 | 223851 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 89244 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 4148 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4290 | 0.020 |
Why?
|
| Middle Aged | 2 | 2020 | 223737 | 0.020 |
Why?
|
| Base Sequence | 1 | 2017 | 12430 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2015 | 2431 | 0.020 |
Why?
|
| Liver | 1 | 2021 | 7578 | 0.020 |
Why?
|
| Male | 3 | 2020 | 365203 | 0.020 |
Why?
|
| Apoptosis | 1 | 2021 | 9527 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 20245 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2015 | 4939 | 0.010 |
Why?
|
| Disease Progression | 1 | 2018 | 13674 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 5804 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9549 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2015 | 9618 | 0.010 |
Why?
|